Carrie Dul, MD
Hematology & Oncology · Grosse Pointe Woods, MINPI 1003820648
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,186 of the $1,643 with a category attached, or 72.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2019 at $901 and has fallen 63.7% since, to $327 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 36 payments — averaging $45.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$374
- Medtronic$285
- Gilead$156
- Lilly USA, LLC$139
- Stemline Therapeutics Inc.$138
- AstraZeneca$120
- plus $431 from 15 others
Across 77 payments — averaging $4296.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$141K
- Genentech, Inc.$115K
- Pfizer$70K
- Merck$5K
What the payments were for
- Speaking & faculty fees$33020%
- Food & beverage$1,18672%
- Education$1278%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $374 |
| Medtronic | 2 | $285 |
| Gilead | 3 | $156 |
| Lilly USA, LLC | 2 | $139 |
| Stemline Therapeutics Inc. | 2 | $138 |
| AstraZeneca(2 entities) | 2 | $120 |
| Seagen Inc. | 1 | $105 |
| Foundation Medicine, Inc. | 1 | $56 |
| Merck | 3 | $35 |
| Exelixis Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Novartis | 2 | $25 |
| Beigene USA, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Sanofi | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,643 in reported general payments places this provider in the 50th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 75 | $1,062,435 |
| IbrancePalbociclib | 61 | $896,497 |
| KisqaliRibociclib Succinate | 36 | $511,073 |
| TruqapCapivasertib | 16 | $330,424 |
| OrserduElacestrant Hcl | 12 | $276,967 |
| Everolimus | 13 | $87,347 |
| EliquisApixaban | 55 | $41,624 |
| Anastrozole | 828 | $32,582 |
| Exemestane | 43 | $13,925 |
| Letrozole | 228 | $7,946 |
| Enoxaparin Sodium | 12 | $6,151 |
| Tamoxifen Citrate | 50 | $1,330 |
| Prochlorperazine Maleate | 33 | $547 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 40 | $487 |
| Alendronate Sodium | 67 | $416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $139 | $1,062,55388 claims |
| PfizerIbrance, Eliquis | $374 | $938,121116 claims |
| NovartisKisqali | $25 | $511,07336 claims |
| AstraZenecaTruqap | $120 | $330,42416 claims |
| Stemline Therapeutics Inc.Orserdu | $138 | $276,96712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grosse Pointe Woods
- Daniel LebovicGrosse Pointe Woods$352K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.